Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC

Phase 2

Not yet recruiting

Conditions: HNSCC
Head and Neck Cancer
Head Cancer Neck
Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Carboplatin
Drug: Tislelizumab
Drug: Polymeric Micellar Paclitaxel
Procedure: Surgical Resection of Primary +/- Neck Dissection
Radiation: Post-operative radiation therapy

First Posted Date: 2024-04-16

Last Posted Date: 2024-04-16

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 85

Registration Number: NCT06366945

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

Phase 2

Not yet recruiting

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Pembrolizumab
Drug: Carboplatin
Drug: Paclitaxel
Drug: Pemetrexed
Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2024-04-15

Last Posted Date: 2024-10-18

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 24

Registration Number: NCT06364917

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

Phase 1

Recruiting

Conditions: Extensive Stage-small Cell Lung Cancer

Interventions: Drug: Ifinatamab deruxtecan
Drug: Atezolizumab
Drug: Carboplatin

First Posted Date: 2024-04-12

Last Posted Date: 2024-11-22

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 123

Registration Number: NCT06362252

Locations: 🇺🇸
University of Alabama -Birmingham, Birmingham, Alabama, United States
🇺🇸
David Geffen School of Medicine, Los Angeles, California, United States
🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States

and more 46 locations

Tislelizumab in Combination With Chemotherapy as a Neoadjuvant Treatment for Advanced Endometrial Cancer

Not Applicable

Not yet recruiting

Conditions: Endometrial Neoplasms

Interventions: Drug: Tislelizumab
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2024-04-12

Last Posted Date: 2024-04-12

Lead Sponsor: Zhongnan Hospital

Target Recruit Count: 20

Registration Number: NCT06363708

Locations: 🇨🇳
The Central Hospital of Wuhan, Wuhan, Hubei, China
🇨🇳
Hubei maternal and child health care hospital, Wuhan, Hubei, China
🇨🇳
Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China

ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC

Phase 1

Recruiting

Conditions: Breast Cancer Female
Breast Cancer
Hormone Receptor Negative Malignant Tumor Breast Triple
HER2-negative Breast Cancer
Triple Negative Breast Cancer

Interventions: Drug: Azenosertib
Drug: Carboplatin
Drug: Pembrolizumab

First Posted Date: 2024-04-08

Last Posted Date: 2024-12-18

Lead Sponsor: Filipa Lynce, MD

Target Recruit Count: 78

Registration Number: NCT06351332

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure

Phase 2

Recruiting

Conditions: Non-Squamous Non-Small Cell Lung Cancer

Interventions: Drug: Serplulimab
Drug: Bevacizumab Biosimilar HLX04
Drug: Pemetrexed
Drug: Carboplatin

First Posted Date: 2024-03-28

Last Posted Date: 2024-03-28

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 46

Registration Number: NCT06334757

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)

Phase 1

Recruiting

Conditions: Thoracic Tumors
Non-small Cell Lung Cancer

Interventions: Drug: AMG 193
Drug: Carboplatin
Drug: Sotorasib
Drug: Paclitaxel
Drug: Pemetrexed
Drug: Pembrolizumab

First Posted Date: 2024-03-27

Last Posted Date: 2024-12-06

Lead Sponsor: Amgen

Target Recruit Count: 500

Registration Number: NCT06333951

Locations: 🇯🇵
Aichi Cancer Center, Nagoya-shi, Aichi, Japan
🇺🇸
Virginia Cancer Specialists PC, Fairfax, Virginia, United States
🇺🇸
Northwest Medical Specialties, PLLC, Tacoma, Washington, United States

and more 27 locations